drugset / Trial / NCT03954756

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

NCT03954756 ↗

Phase 2 Unknown 35 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced Gastric Cancer.

Timeline

Start
2019-06-01
Primary completion
2021-06-01
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg Oral

Indications